Stockreport

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens without Conditioning Chemot [Read more]